Krakowczyk Dominika, Szeliga Kamila, Chyra Marcin, Pietrowska Monika, Koszutski Tomasz, Gawlik-Starzyk Aneta, Hyla-Klekot Lidia
Saint John Paul II Upper Silesian Child Health Centre, Public Clinical Hospital no.6 of the Medical University of Silesia in Katowice, Medyków 16 Street, 40-752 Katowice, Poland.
Department of Pediatric Neurology, Independent Public Healthcare Centre-Municipal Hospital Complex, ul.W. Truchana 7, 41-500 Chorzow, Poland.
Int J Mol Sci. 2025 Sep 2;26(17):8522. doi: 10.3390/ijms26178522.
Childhood obesity has emerged as one of the most pressing public health challenges of the 21st century. Early-onset obesity is associated with an increased risk of developing numerous comorbidities later in life. Despite extensive research into its multifactorial etiology-including genetic, behavioral, environmental, and socioeconomic factors-the precise molecular mechanisms underlying the development and persistence of obesity in the pediatric population remain incompletely understood. Proteomics offers promising insights into these mechanisms. The application of proteomics in pediatric obesity research has grown, enabling the identification of proteins that reflect dynamic changes in metabolic and inflammatory pathways. This advancement allows clinicians to move beyond traditional anthropometric measurements toward personalized approaches with notification of early complications of obesity. A systematic search was conducted across PubMed, Scopus, and Web of Science for studies published between 2010 and 2025. Inclusion criteria: human studies, participants aged 0-18, proteomic analysis of obesity, and biomarkers. Data extraction and quality assessment followed standardized protocols. From 239 articles, 20 were included. Key dysregulated proteins include APOA1, CLU, and HP. LC-MS/MS was the predominant technique used. Some biomarkers were predictive for obesity complications in children. Proteomics holds clinical potential for early detection and personalized treatment of pediatric obesity. Standardized methodologies and longitudinal studies are needed for translation into clinical practice.
儿童肥胖已成为21世纪最紧迫的公共卫生挑战之一。早发性肥胖与日后患多种合并症的风险增加有关。尽管对其多因素病因进行了广泛研究,包括遗传、行为、环境和社会经济因素,但儿科人群中肥胖发生和持续存在的精确分子机制仍未完全了解。蛋白质组学为这些机制提供了有前景的见解。蛋白质组学在儿科肥胖研究中的应用不断增加,能够识别反映代谢和炎症途径动态变化的蛋白质。这一进展使临床医生能够超越传统的人体测量方法,转向针对肥胖早期并发症进行告知的个性化方法。我们在PubMed、Scopus和Web of Science上进行了系统检索,以查找2010年至2025年发表的研究。纳入标准:人体研究、0至18岁参与者、肥胖的蛋白质组学分析以及生物标志物。数据提取和质量评估遵循标准化方案。从239篇文章中,纳入了20篇。关键的失调蛋白包括载脂蛋白A1、簇集蛋白和触珠蛋白。液相色谱-串联质谱法是主要使用的技术。一些生物标志物可预测儿童肥胖并发症。蛋白质组学在儿科肥胖的早期检测和个性化治疗方面具有临床潜力。需要标准化方法和纵向研究以转化为临床实践。